We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Novo Holdings and Gurnet Point Capital have wrapped up the previously announced $462m acquisition of Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company based in the US. Paratek Pharmaceuticals is
Merck and Eisai have reported mixed-bag results from the Phase 3 LEAP-010 trial for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) in a type of head and neck squamous cell
American Chemical Society’s scientific information solutions unit CAS is teaming up with Molecule.one to expedite drug discovery by jointly developing computer-aided synthesis design technologies. Molecule.one is a provider
US-based biotechnology company HebeCell is joining forces with Japanese synthetic biology firm Logomix for the development of the next-generation genomically engineered PSC-NK cells. HebeCell is engaged in developing
Nutritional Research, a US-based supplier of vitamins and supplements, said that it has launched the ABSORBABLE range of supplements globally on the Amazon website. The launched range includes
Zumutor Biologics Inc “Zumutor”, a Boston based biopharmaceutical company focused on developing unique novel therapeutics in immuno-oncology (I-O) today announces that the US Food and Drug Administration (FDA) has granted the
Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines
GSK has secured approval for Jemperli (dostarlimab) plus chemotherapy from the US Food and Drug Administration (FDA) for the treatment of a type of endometrial cancer in adult
Nanjing Leads Biolabs (Leads Biolabs) has been given clearance to hold clinical trials for its anti-GPRC5D/CD3 bispecific antibody LBL-034 in relapsed/refractory multiple myeloma in the US and China.
AbbVie and Genmab said that their jointly developed epcoritamab (DuoBody-CD3xCD20) has shown positive results in a Phase 1/2 trial in patients having relapsed/refractory (R/R) follicular lymphoma (FL). The